Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Therapeutic Drug Carrier Systems
Impact-faktor: 2.9 5-jähriger Impact-Faktor: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Druckformat: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v26.i4.10
pages 333-372

Paclitaxel in Cancer Treatment: Perspectives and Prospects of its Delivery Challenges

Somnath Singh
Department of Pharmacy Sciences, School of Pharmacy and Health Professions, Creighton University, Omaha, Nebraska
Alekha K. Dash
Creighton University

ABSTRAKT

Paclitaxel (PTX) is a potent anticancer agent whose clinical usefulness is marred by a delivery problem that is caused by its unfavorable pharmacokinetic and physical properties. Paclitaxel is currently formulated in a mixture of Cremophor EL and ethanol, which is diluted 5−20 times with normal saline or 5% dextrose prior to administration via slow infusion to avoid precipitation in plasma. Many adverse reactions to the PTX formulation have been reported because of the presence of Cremophor EL, including hypersensitivity reactions, nephrotoxicity, and neurotoxicity. Cremophor EL also causes vasodilation, labored breathing, lethargy, hypotension, and leaching of plasticizers, such as diethylhexylpthalate, from the polyvinylchloride infusion bags/sets. Significant research efforts have been conducted to develop an alternative formulation approach to increase the aqueous solubility of PTX without using Cremophor, thereby decreasing its toxicity. This article reviews the various investigated formulation approaches including pastes; liposomes; conjugates with antibodies, peptides, and fatty acids; nanospheres and microspheres; cyclodextrin complexes; emulsions; mucoadhesive gel; prodrugs; and nanoparticulate systems. The pros and cons of each approach are also discussed. Finally, this review concludes with a discussion of nanoparticulate delivery, which is the most promising PTX delivery system of the future because it incorporates the benefits of other approaches such as conjugation, complexation, and prodrugs.


Articles with similar content:

Enhancement of Ocular Drug Penetration
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.16, 1999, issue 1
Junzo Nakamura, Mikiro Nakashima, Masataka Ichikawa, Takahiro Mukai, Hitoshi Sasaki, Kenzo Yamamura, Koyo Nishida
Enhancement of Transdermal Delivery of Heparin by Various Physical and Chemical Enhancement Techniques
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.26, 2009, issue 6
S. S. Lanke, Ajay K. Banga, J. G. Strom
Heparin-Tailored Biopolymeric Nanocarriers in Site-Specific Delivery: A Systematic Review
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 1
Awesh K. Yadav, Rajeev Sharma, Ashish Garg, Vikas Pandey, Vaibhav Patel
The Synthesis of C8-Aryl Purines, Nucleosides and Phosphoramidites
Critical Reviews™ in Eukaryotic Gene Expression, Vol.21, 2011, issue 2
Nissa M. Thomsen, Peter Gannett, Vorasit Vongsutilers
Recent Advances in Self-Emulsifying Drug Delivery Systems (SEDDS)
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 2
Premjeet Singh Sandhu, Ravinder Kaur, Sarwar Beg, Bhupinder Singh, Om Parkash Katare, Rajneet Kaur Khurana